查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1421610

骨髓增生性疾病治疗市场、份额、规模、趋势、行业分析报告：按类型、按治疗、按最终用途、按地区、按细分市场、预测，2023-2032 年

Myeloproliferative Disorder Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Polycythaemia Vera, Essential Thrombocythemia, Myelofibrosis, Other), By Treatment, By End-Use, By Region, And Segment Forecasts, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，到 2032 年，全球骨髓增生性疾病治疗市场规模预计将达到 131.3 亿美元。 该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

新药的供应量正在增加，并且存在强大的潜在治疗方法。 这让人乐观地认为未来将会出现更有效的治疗方法，从而推动市场的兴趣和投资。 由于生活方式的改变和人口老化，骨髓增生性疾病的盛行率不断增加。 这些因素增加了这些疾病的风险人数，并增加了对治疗的需求。

此外，大众对骨髓增生性疾病的认识也不断提高。 这种意识的提高导致了早期诊断和早期治疗，进一步增加了该市场对治疗药物的需求。 此外，为无法耐受 Jakafi 的患者开发治疗方案是一个值得注意的趋势，Jakafi 常用于治疗骨髓增生性疾病。 这种二线治疗满足了对 Jakafi 没有反应的患者的需求，并扩大了市场的潜在患者基础。

慢性骨髓增生性疾病（MPD）是一组罕见的血液系统恶性肿瘤，其特征是骨髓和周边血液中某些血球的异常增生。 这些疾病主要影响骨髓谱系及其前驱细胞，包括红血球、粒细胞（白血球的一种）和血小板。 这些疾病根据费城染色体的存在或不存在进一步分类。 费城染色体是一种特定的遗传异常，由 9 号和 22 号染色体之间的易位（遗传物质交换）引起。 费城染色体的存在是 CML 的标誌。

慢性骨髓增生性疾病是一种复杂的疾病，需要医疗专业人员仔细诊断和治疗。 治疗选择包括控制血球数、控制症状和降低併发症风险的药物。 在某些情况下，干细胞移植可被视为一种治疗方法。

北美和西欧的骨髓增生性疾病（MPN）发生率高于东亚国家，被认为是由多种因素造成的，包括遗传倾向、生活方式和环境因素的差异。 儘管大多数 MPN 患者在 60 岁后被诊断出来，但这些疾病可以在任何年龄发生。 美国因其人口众多、医疗基础设施先进以及研发投入巨大，可提供MPN创新疗法，因此成为MPN药物最有可能的市场，令人期待。

骨髓增生性疾病治疗市场报告亮点

  • 由于病例数增加以及为提高治疗效果而加强研发力度，骨髓纤维化领域占最大比例。
  • 饮食变化和忙碌的生活方式导致癌症病例迅速增加，推动了化疗行业的发展
  • 由于其发达的医疗基础设施以及工业界和学术界在研发方面的积极合作，北美占据了最大的市场份额。
  • 主要参与者包括诺华 (Novartis)、百时美施贵宝 (Bristol-Myers)、Incyte Corp、武田製药 (Takeda Pharmaceuticals)、Viatris、艾伯维 (AbbVie) 和梯瓦製药 (Teva Pharmaceuticals)。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第 4 章全球骨髓增生性疾病治疗市场洞察

  • 骨髓增生性疾病治疗市场 - 最终用途概况
  • 骨髓增生性疾病治疗市场动态
    • 推动者和机会
      • 对有效治疗的需求不断增加
      • 研发和分子理解的进展
    • 抑制因素和挑战
      • 治疗选择有限
  • PESTEL 分析
  • 骨髓增生性疾病治疗市场最终用途趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第五章全球骨髓增生性疾病治疗市场（依类型）

  • 主要调查结果
  • 简介
  • 真性红血球增多症
  • 原发性血小板增多症
  • 骨髓纤维化
  • 其他

第 6 章全球骨髓增生性疾病治疗市场（依治疗）

  • 主要调查结果
  • 简介
  • 化疗
  • 免疫治疗
  • 干细胞移植
  • 其他

第 7 章全球骨髓增生性疾病治疗市场，依最终用途划分

  • 主要调查结果
  • 简介
  • 医院
  • 专科诊所
  • 其他

第 8 章全球骨髓增生性疾病治疗市场（按地区）

  • 主要调查结果
  • 简介
    • 2019-2032 年各地区骨髓增生性疾病治疗市场评估
  • 骨髓增生性疾病治疗市场 - 北美
    • 北美：骨髓增生性疾病治疗市场（依类型），2019-2032 年
    • 北美：骨髓增生性疾病治疗市场（以最终用途），2019-2032 年
    • 北美：骨髓增生性疾病治疗市场（依治疗方式），2019-2032 年
    • 骨髓增生性疾病治疗市场 - 美国
    • 骨髓增生性疾病治疗市场 - 加拿大
  • 骨髓增生性疾病治疗市场 - 欧洲
    • 欧洲：骨髓增生性疾病治疗市场（依类型），2019-2032 年
    • 欧洲：骨髓增生性疾病治疗市场（以最终用途），2019-2032 年
    • 欧洲：骨髓增生性疾病治疗市场（依治疗方式），2019-2032 年
    • 骨髓增生性疾病治疗市场 - 英国
    • 骨髓增生性疾病治疗市场 - 法国
    • 骨髓增生性疾病治疗市场 - 德国
    • 骨髓增生性疾病治疗市场 - 义大利
    • 骨髓增生性疾病治疗市场 - 西班牙
    • 骨髓增生性疾病治疗市场 - 荷兰
    • 骨髓增生性疾病治疗市场 - 俄罗斯
  • 骨髓增生性疾病治疗市场 - 亚太地区
    • 亚太地区：骨髓增生性疾病治疗市场（按类型），2019-2032 年
    • 亚太地区：骨髓增生性疾病治疗市场（依最终用途），2019-2032 年
    • 亚太地区：骨髓增生性疾病治疗市场（依治疗方式），2019-2032 年
    • 骨髓增生性疾病治疗市场 - 中国
    • 骨髓增生性疾病治疗市场 - 印度
    • 骨髓增生性疾病治疗市场 - 马来西亚
    • 骨髓增生性疾病治疗市场 - 日本
    • 骨髓增生性疾病治疗市场 - 印度尼西亚
    • 骨髓增生性疾病治疗市场 - 韩国
  • 骨髓增生性疾病治疗市场 - 中东和非洲
    • 中东和非洲：骨髓增生性疾病治疗市场（按类型），2019-2032 年
    • 中东和非洲：骨髓增生性疾病治疗市场（以最终用途），2019-2032 年
    • 中东与非洲：骨髓增生性疾病治疗市场（依治疗方式），2019-2032 年
    • 骨髓增生性疾病治疗市场 - 沙乌地阿拉伯
    • 骨髓增生性疾病治疗市场 - 阿拉伯联合大公国
    • 骨髓增生性疾病治疗市场 - 以色列
    • 骨髓增生性疾病治疗市场 - 南非
  • 骨髓增生性疾病治疗市场 - 拉丁美洲
    • 拉丁美洲：骨髓增生性疾病治疗市场（按类型），2019-2032 年
    • 拉丁美洲：骨髓增生性疾病治疗市场（以最终用途），2019-2032 年
    • 拉丁美洲：骨髓增生性疾病治疗市场（依治疗方式），2019-2032 年
    • 骨髓增生性疾病治疗市场 - 墨西哥
    • 骨髓增生性疾病治疗市场 - 巴西
    • 骨髓增生性疾病治疗市场 - 阿根廷

第九章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第十章公司简介

  • AbbVie
  • Bristol-Myers Squibb
  • Incyte Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals
  • Viatris（Mylan N.V.）
Product Code: PM3936

The global myeloproliferative disorders treatment market size is expected to reach USD 13.13 billion by 2032, according to a new study by Polaris Market Research. The report "Myeloproliferative Disorder Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Polycythaemia Vera, Essential Thrombocythemia, Myelofibrosis, Other), By Treatment, By End-Use, By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

There is a growing availability of novel drugs and a strong pipeline of potential treatments. This has created optimism for more effective therapies in the future, driving interest and investment in the market. The rising incidence of myeloproliferative disorders can be attributed to changing lifestyles and an aging population. These factors have contributed to an increase in the number of individuals at risk of developing these conditions, leading to a higher demand for treatments.

Additionally, there is a heightened level of public awareness regarding myeloproliferative disorders. This increased awareness has led to earlier diagnosis and treatment, further fueling the demand for therapies in the market. Furthermore, the development of therapeutic options for patients who are intolerant to Jakafi, a commonly used medication for myeloproliferative disorders, is a notable trend. This second-line treatment approach addresses the needs of patients who may not respond well to Jakafi, expanding the market's potential patient base.

Chronic myeloproliferative disorders (MPDs) are a group of rare hematological malignancies characterized by the abnormal proliferation of certain types of blood cells in the bone marrow and peripheral blood. These disorders primarily affect the myeloid cell line, which includes red blood cells, granulocytes (a type of white blood cell), and platelets, as well as their precursor cells. These disorders are further categorized based on the presence or absence of the Philadelphia chromosome. The Philadelphia chromosome is a specific genetic abnormality resulting from a translocation (exchange of genetic material) between chromosomes 9 and 22. Its presence is a defining characteristic of CML.

Chronic myeloproliferative disorders are complex conditions that require careful diagnosis and management by healthcare professionals. Treatment options may include medications to control blood cell counts, manage symptoms, and reduce the risk of complications. In some cases, stem cell transplantation may be considered as a curative treatment option.

The higher incidence of myeloproliferative disorders (MPNs) in North America & Western Europe compared to East-Asian countries can be attributed to various factors, including differences in genetic predisposition, lifestyle, and environmental factors. While most MPN patients are diagnosed after the age of 60, these disorders can affect individuals of any age. The United States is poised to be the most prominent market for MPN drugs due to its substantial target population, advanced healthcare infrastructure, and significant investments in research and development, leading to the availability of innovative treatments for MPNs.

Myeloproliferative Disorders Treatment Market Report Highlights

  • The myelofibrosis segment held the largest share, owing to rising cases & increased research & development efforts to increase the efficacy of the treatment procedures
  • Chemotherapy segment led the market on account of a surge in cases of cancers due to changes in diet and busier lifestyle
  • North America garnered the largest share due to the presence of well-developed medical infrastructure, & huge industry-academia efforts for research & innovations
  • Key players include Novartis, Bristol-Myers, Incyte Corp, Takeda Pharmaceutical, Viatris, AbbVie, and Teva Pharmaceuticals

Polaris Market Research has segmented the myeloproliferative disorders treatment market report based on type, treatment, end-use, and region:

Myeloproliferative Disorders Treatment, Type Outlook (Revenue - USD Billion, 2023 - 2032)

  • Polycythaemia Vera
  • Essential Thrombocythemia
  • Myelofibrosis
  • Others

Myeloproliferative Disorders Treatment, Treatment Outlook (Revenue - USD Billion, 2023 - 2032)

  • Chemotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others

Myeloproliferative Disorders Treatment, End-Use Outlook (Revenue - USD Billion, 2023 - 2032)

  • Hospitals
  • Specialty Clinics
  • Others

Myeloproliferative Disorders Treatment, Regional Outlook (Revenue - USD Billion, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Myeloproliferative Disorder Treatment Market Insights

  • 4.1. Myeloproliferative Disorder Treatment Market - End-Use Snapshot
  • 4.2. Myeloproliferative Disorder Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Growing demand for effective treatments
      • 4.2.1.2. Advancements in R&D and molecular understanding
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited treatment options
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Myeloproliferative Disorder Treatment Market End-Use Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Myeloproliferative Disorder Treatment Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Polycythaemia Vera
    • 5.3.1. Global Myeloproliferative Disorder Treatment Market, by Polycythaemia Vera, by Region, 2019-2032 (USD Billion)
  • 5.4. Essential Thrombocythemia
    • 5.4.1. Global Myeloproliferative Disorder Treatment Market, by Essential Thrombocythemia, by Region, 2019-2032 (USD Billion)
  • 5.5. Myelofibrosis
    • 5.5.1. Global Myeloproliferative Disorder Treatment Market, by Myelofibrosis, by Region, 2019-2032 (USD Billion)
  • 5.6. Other
    • 5.6.1. Global Myeloproliferative Disorder Treatment Market, by Other, by Region, 2019-2032 (USD Billion)

6. Global Myeloproliferative Disorder Treatment Market, by Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 6.3. Chemotherapy
    • 6.3.1. Global Myeloproliferative Disorder Treatment Market, by Chemotherapy, by Region, 2019-2032 (USD Billion)
  • 6.4. Immunotherapy
    • 6.4.1. Global Myeloproliferative Disorder Treatment Market, by Immunotherapy, by Region, 2019-2032 (USD Billion)
  • 6.5. Stem Cell Transplantation
    • 6.5.1. Global Myeloproliferative Disorder Treatment Market, by Stem Cell Transplantation, by Region, 2019-2032 (USD Billion)
  • 6.6. Other
    • 6.6.1. Global Myeloproliferative Disorder Treatment Market, by Other, by Region, 2019-2032 (USD Billion)

7. Global Myeloproliferative Disorder Treatment Market, by End-Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • 7.3. Hospitals
    • 7.3.1. Global Myeloproliferative Disorder Treatment Market, by Hospitals, By Region, 2019-2032 (USD Billion)
  • 7.4. Specialty Clinics
    • 7.4.1. Global Myeloproliferative Disorder Treatment Market, by Specialty Clinics, By Region, 2019-2032 (USD Billion)
  • 7.5. Other
    • 7.5.1. Global Myeloproliferative Disorder Treatment Market, by Other, By Region, 2019-2032 (USD Billion)

8. Global Myeloproliferative Disorder Treatment Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Myeloproliferative Disorder Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Myeloproliferative Disorder Treatment Market - North America
    • 8.3.1. North America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.3.3. North America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.4. Myeloproliferative Disorder Treatment Market - U.S.
      • 8.3.4.1. U.S.: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.5. Myeloproliferative Disorder Treatment Market - Canada
      • 8.3.5.1. Canada: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 8.4. Myeloproliferative Disorder Treatment Market - Europe
    • 8.4.1. Europe: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.4. Myeloproliferative Disorder Treatment Market - UK
      • 8.4.4.1. UK: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.5. Myeloproliferative Disorder Treatment Market - France
      • 8.4.5.1. France: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.6. Myeloproliferative Disorder Treatment Market - Germany
      • 8.4.6.1. Germany: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.7. Myeloproliferative Disorder Treatment Market - Italy
      • 8.4.7.1. Italy: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.8. Myeloproliferative Disorder Treatment Market - Spain
      • 8.4.8.1. Spain: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.9. Myeloproliferative Disorder Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.10. Myeloproliferative Disorder Treatment Market - Russia
      • 8.4.10.1. Russia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 8.5. Myeloproliferative Disorder Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.4. Myeloproliferative Disorder Treatment Market - China
      • 8.5.4.1. China: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.5. Myeloproliferative Disorder Treatment Market - India
      • 8.5.5.1. India: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.6. Myeloproliferative Disorder Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.7. Myeloproliferative Disorder Treatment Market - Japan
      • 8.5.7.1. Japan: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.8. Myeloproliferative Disorder Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.9. Myeloproliferative Disorder Treatment Market - South Korea
      • 8.5.9.1. South Korea: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 8.6. Myeloproliferative Disorder Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.4. Myeloproliferative Disorder Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.5. Myeloproliferative Disorder Treatment Market - UAE
      • 8.6.5.1. UAE: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.6. Myeloproliferative Disorder Treatment Market - Israel
      • 8.6.6.1. Israel: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.7. Myeloproliferative Disorder Treatment Market - South Africa
      • 8.6.7.1. South Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 8.7. Myeloproliferative Disorder Treatment Market - Latin America
    • 8.7.1. Latin America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.4. Myeloproliferative Disorder Treatment Market - Mexico
      • 8.7.4.1. Mexico: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.5. Myeloproliferative Disorder Treatment Market - Brazil
      • 8.7.5.1. Brazil: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.6. Myeloproliferative Disorder Treatment Market - Argentina
      • 8.7.6.1. Argentina: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Bristol-Myers Squibb
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Incyte Corporation
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Novartis AG
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Takeda Pharmaceutical Company Limited
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Teva Pharmaceuticals
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Viatris (Mylan N.V.)
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development

List of Tables

  • Table 1 Global Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 3 Global Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 4 Myeloproliferative Disorder Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 7 North America: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 8 U.S.: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 10 U.S.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 11 Canada: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 13 Canada: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 14 Europe: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 16 Europe: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 17 UK: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 19 UK: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 20 France: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 22 France: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 23 Germany: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 25 Germany: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 26 Italy: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 28 Italy: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 29 Spain: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 31 Spain: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 35 Russia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 37 Russia: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 41 China: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 43 China: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 44 India: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 46 India: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 50 Japan: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 52 Japan: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 56 South Korea: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 58 South Korea: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 65 UAE: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 67 UAE: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 68 Israel: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 70 Israel: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 71 South Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 73 South Africa: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 74 Latin America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 76 Latin America: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 77 Mexico: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 79 Mexico: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 80 Brazil: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 82 Brazil: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 83 Argentina: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 85 Argentina: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Myeloproliferative Disorder Treatment Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Myeloproliferative Disorder Treatment Market, by Treatment, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Myeloproliferative Disorder Treatment Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by End-Use
  • Figure 11. Global Myeloproliferative Disorder Treatment Market, by End-Use, 2022 & 2032 (USD Billion)
  • Figure 12. Myeloproliferative Disorder Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Myeloproliferative Disorder Treatment Market